Ftfy bit rude isnt it ? i prefer being honest and open in discussion rather than cloud my expressions with internet nomenclature spps are expensive to launch to gain little $ traction money is more than freely available to this company in many structures - direct new shareholder institutional placement placement to existing soph shareholders government grants - we will most likely see some soon given whats going on here ( csiro doherty etc) plus in the usa where they are tossing around billions ( non dilutive) intermediate brokers must be knocking on the door every day offering funds for a relevant tranche of shares the fact that the company hasnt gone that route has to be admired through large skin in the game they no more want dilution than we do in the mid term event that funds are required the taps are open and the company has no doubt multiple choices they anticipate that by then much higher valuations will prevail so less shares needed to achieve funding goals with the likelyhood therefore of a fully funded to phase three fda program and other multiple opportunities on now 6 fronts ( helio bac today added in ) with less than 200 mill shares on issue- the potential valuation per share is, in my opinion, going to impress
2, 3 -5 - 10 $ etc not out of the question later this year or next repeat - the valuation of this company is uncapped research on its potential longer term valuation is almost non existent by brokers but its valuation base parameters keep expanding month by month the mcap of this company was less than $20 mill at the first raise at 14c , then at 26c raise it lifted to around $ 38 ish remind me now oscillating around $200 mill only 148 m on issue with 40% near enough insiders hard to keep up with the expansion here but a billion plus market cap would not surprise even on the most conservative basis of calculation
as i said and i still stand by my expectations that this revaluation process could lead to some extraordinary sp outcomes ” uncapped” remember that next year or so bpharma cheers
RCE Price at posting:
$1.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)